Virpax Pharmaceuticals, Inc. (VRPX) [Rocket]

In millions, except per share items	Jun-30-23	Mar-31-23	Dec-31-22	Sep-30-22	Jun-30-22	Mar-31-22	Dec-31-21	Sep-30-21
	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q
Revenues	15.2	18.0	21.4	32.7	28.2	24.7	22.1
Revenue growth	-46.0%	-27.4%	-3.3%
Cost of goods sold	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Gross profit	15.2	18.0	21.4	32.7	28.2	24.7	22.1
Gross margin	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Selling, general and administrative [+]	10.0	10.7	12.2	13.1	9.8	9.2	8.9
General and administrative	10.0	10.7	12.2	13.1	9.8	9.2	8.9
Research and development	5.6	7.6	9.7	11.2	10.0	7.1	4.8
Other operating expenses	15.7	18.4	21.8	30.8	26.3	22.7	19.9
EBIT [+]	-16.1	-18.8	-22.3	-22.4	-17.9	-14.3	-11.5
EBIT growth	-10.0%	31.3%	93.7%
EBIT margin	-105.5%	-104.5%	-104.1%	-68.4%	-63.4%	-57.8%	-52.0%
Non-recurring items		-0.4	-0.5				0.5
Interest expense							0.1
Interest expense							0.1
Other income (expense), net	0.4	0.3	0.2	0.1	0.1	0.1	0.1
Pre-tax income	-15.3	-18.0	-21.7	-22.8	-18.4	-14.8	-12.1
Income taxes	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net income	-15.3	-18.0	-21.7	-22.8	-18.4	-14.8	-12.1
Net margin	-100.1%	-100.5%	-101.1%	-69.7%	-65.0%	-59.9%	-54.4%

Basic EPS [+]	($1.30)	($1.54)	($1.85)	($2.18)	($2.03)	($2.02)	($2.23)
Growth	-35.9%	-23.7%	-17.2%
Diluted EPS [+]	($1.30)	($1.54)	($1.85)	($2.18)	($2.03)	($2.02)	($2.23)
Growth	-35.9%	-23.7%	-17.2%

Shares outstanding (basic) [+]	11.7	11.7	11.7	10.5	9.0	7.3	5.4
Growth	29.8%	59.6%	117.0%
Shares outstanding (diluted) [+]	11.7	11.7	11.7	10.5	9.0	7.3	5.4
Growth	29.8%	59.6%	117.0%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.